EVOLUTION AT MERCK - INVENTING FOR LIFE
Percentage Change From Baseline
KEYTRUDA: EARLY STAGE PROSTATE CANCER
DATA INFORM PHASE 3 DEVELOPMENT PROGRAM
KEYNOTE-365 Cohort A
80-
KEYTRUDA+Lynparza
PCW3-Modified RECIST V1.1a,b
11/28 (39%) experienced reduction in tumor burden
60
40
• 8/28 (29%) experienced reduction ≥30%
20
-20-
-40-
-60-
PD-L1+
-80-
PD-L1 and Unknown
-100-
+20%
-30%
Percentage Change From Baseline
100
BO
60-
40-
20-
0
-20-
-40-
-60-
-80-
-100
KEYNOTE-365 Cohort B
KEYTRUDA+Docetaxel
30/36 (83%) experienced reduction in tumor burden
11/36 (31%) experienced reduction 2.30%
PD-L1+
PD-L1-and Unknown
+20%
-30%
Percentage Change From Baseline
100
80
KEYNOTE-365 Cohort C
KEYTRUDA+Enzalutamide
60-
40-
20
0
-20
-40-
-60-
-80
-100
11/25 (44%) experienced reduction in tumor burden
6/25 (24%) experienced reduction ≥ 30%
PD-L1+
PD-L1- and unknown
+20%
-30%
54
MERCK
INVENTING FOR LIFE
#
Dr. Roy Baynes HView entire presentation